Clinical Trial Update: A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) [Phase 1]

View source ↗

Summary

A Phase I trial evaluating IMA970A plus Montanide in combination with durvalumab (anti-PD-L1) for hepatocellular carcinoma is currently active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IMA970A
• IMFINZI (DURVALUMAB)
• Montanide (Montanide adjuvant)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING